Barclays Rates DuPont de Nemours (DD) Overweight

On October 13, 2026, Barclays reaffirmed its Overweight rating on DuPont with a price target of $156, a 19.85% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:23 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays rated DuPont de Nemours, Inc. ($DD) "Overweight" with a $156 price target on October 13, 2026.

Since the rating, $DD is up 0.7% to date (from the $129.55 close on Oct 13, 2026).

DD DuPont de Nemours, Inc.

$130.45 +7.72% year to date

Daily close · Oct 16, 2026

Key Points

Barclays reiterated its Overweight rating on DuPont de Nemours, Inc. with a new price target of $156 on October 13, 2026.
Barclays's $156 price target implies 19.85% upside from DuPont de Nemours, Inc.'s ($DD) current $130.16 share price.
Shares of DuPont recently traded at $130.16, which is 16.6% below Barclays' price target.
DuPont's next earnings report is scheduled for November 5, 2026, providing insight into its financial performance.

Get $DD trade alerts by text

We text you when insiders, Congress or big funds trade $DD. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated DuPont de Nemours, Inc. alert may contain errors. Disclosures

On October 13, 2026, Barclays reiterated its Overweight rating on DuPont de Nemours, Inc. (NYSE: DD) with a price target of $156. This new target comes as shares of DuPont recently traded at $130.16, placing them about 16.6% below the target price set by Barclays.

Firm's Call on DuPont

Barclays' reaffirmation of its Overweight rating suggests confidence in DuPont's potential for growth. The firm set a price target of $156, which aims to capture the company's expected performance in the specialty chemicals sector. This call comes amid a backdrop of mixed analyst activity, including other firms maintaining or adjusting their ratings on DuPont in recent weeks.

Other Institutional Activity in DuPont

Several other institutional investors have shown interest in DuPont. Blackrock Inc. increased its holdings by 250,339 shares, ending with 10,637,868 shares worth about $1.39 billion. State Street Corporation grew its position by 715,117 shares, bringing its total to 6,949,792 shares valued at approximately $906.7 million. Meanwhile, Vanguard Capital Management LLC added 70,918 shares, totaling 8,935,728 shares worth about $1.17 billion.

DuPont de Nemours, Inc. Stock Down 1.1%

Shares of DuPont are currently trading at $130.16. This price is notably below Barclays' target of $156, indicating potential upside for investors if the company meets its growth expectations. The stock's performance in the coming weeks will be closely watched, especially with the next earnings report approaching.

12-month forecast

$DD price target

DuPont de Nemours, Inc. daily closes and this analyst's $156 target. Not advice.

Recent Earnings

DuPont reported trailing twelve-month revenue of approximately $6.99 billion. The company has a net margin of 0.8% and a return on equity of 1.8%. Its next earnings report is expected on November 5, 2026, which could provide further clarity on its financial health and growth trajectory.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

C 60/100

Reported May 5, 2026

Forward outlook
1 analysts raised price targets.
EPS & revenue
EPS beat estimates by 10.4%. Revenue missed estimates by 2.0%.
Profit surprise
EBITDA missed by 46 percent. Operating income missed by 52 percent.
Pre-earnings setup
Bar was high, analysts already very bullish.
Analyst signal
1 target raise.
Earnings quality
Gross margin up 3.2 points. Operating margin down 5.0 points. Positive free cash flow.

Earnings Call Summary

DuPont delivered a strong first quarter with organic sales growth of 2 percent and 20 percent adjusted earnings growth on a pro forma basis. Healthcare sales were especially strong at high single digit growth, while water was hampered by about $10 million in shipment delays from Middle East logistics disruptions. Management emphasized continued innovation, with plans to launch an AI platform for product development, and noted steady progress on their operational improvement program including Kaizen events. The company completed the Aramids divestiture and announced a $275 million accelerated share buyback, returning capital to shareholders while maintaining balance sheet strength.

Guidance DuPont raised full year sales guidance to about $7.2 billion and adjusted earnings to $2.35 to $2.40 per share. They expect about 4 percent organic growth for the year, including roughly 1 percent from pricing to cover higher raw material costs from the Middle East conflict. The company also projects strong margin expansion through the rest of the year.

Neutral report. Results and guidance were close to expectations, with limited evidence of a reset either way.

Insider Buying and Selling at DuPont de Nemours, Inc.

Recently, Lori Koch, the CEO of DuPont, sold 260 shares on June 2, 2026, at an average price of $48.82, totaling about $12,741. This transaction occurred before the recent analyst activity and reflects typical insider trading behavior.

Analysts Set New Price Targets

On October 13, 2026, Barclays set a price target of $156 for DuPont while maintaining its Overweight rating. Earlier, on October 5, UBS maintained a Buy rating with a target of $172, and Citigroup maintained a Buy rating with a target of $162 on October 7. The consensus among analysts indicates a generally positive outlook for the stock, with various price targets suggesting room for growth.

About DuPont

DuPont de Nemours, Inc. provides technology-based materials and solutions across various sectors, including healthcare and water technologies. Headquartered in Wilmington, DE, the company operates globally, focusing on innovative solutions in the specialty chemicals industry.

Bottom Line

Investors should keep an eye on DuPont's upcoming earnings report on November 5, 2026, as well as any further analyst ratings that may emerge. Barclays' reaffirmed Overweight rating and price target of $156 suggest that there may be potential for growth in the stock, especially as the company continues to navigate its business environment.